IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
Ji, Linong1; Onishi, Yukiko2; Ahn, Chul Woo3; Agarwal, Pankaj4; Chou, Chien-Wen5; Haber, Harry6; Guerrettaz, Kelly7; Boardman, Marilyn K.8
关键词Asian Exenatide Type 2 diabetes
刊名JOURNAL OF DIABETES INVESTIGATION
2013
DOI10.1111/j.2040-1124.2012.00238.x
4期:1页:53-61
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Endocrinology & Metabolism
研究领域[WOS]Endocrinology & Metabolism
关键词[WOS]CROSS-SECTIONAL SURVEY ; BLOOD-GLUCOSE CONTROL ; BETA-CELL FUNCTION ; BODY-MASS INDEX ; GLYCEMIC CONTROL ; INSULIN SENSITIVITY ; RANDOMIZED-TRIAL ; JAPANESE PATIENTS ; TREATED PATIENTS ; OPEN-LABEL
英文摘要

Aims/Introduction To compare safety and efficacy of the extended-release formulation exenatide once weekly (EQW) vs exenatide twice daily (EBID) for 26weeks in type 2 diabetes patients from China, India, Japan, South Korea and Taiwan. Materials and Methods A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] 7 and 11%) with oral antihyperglycemic medications (OAMs). Patients added 2mg EQW or 10g EBID to current OAMs. Safety was re-evaluated 10weeks after last treatment. Results EQW was superior to EBID on HbA1c measures at week 26 (Least-squares mean treatment difference: 0.31% [95% confidence interval 0.49, 0.14%]). More EQW-treated patients achieved target HbA1c 7.0% (P=0.003), 6.5% (P<0.001), or 6.0% (P=0.003). Fasting serum glucose reductions were greater among EQW-treated patients (P<0.001). Bloodglucose profiles improved in both treatment groups (P<0.001). Weight loss occurred with both treatments, but was greater with EBID. Adverse events (10%, either group) were nausea, injection-site induration, dyslipidemia and vomiting. Injection-site induration was more frequent with EQW, whereas nausea, vomiting and hypoglycemia were less frequent. One episode each of major hypoglycemia (EBID) and pancreatitis (EQW) were reported. Conclusion In this population, EQW and EBID showed efficacious glucose and weight control; safety and tolerability were consistent with observations in non-Asian patients. This trial was registered with ClinicalTrials.gov (no. NCT00917267).

语种英语
WOS记录号WOS:000314242900009
资助机构Eli Lilly and Company
引用统计
被引频次:42[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64127
专题北京大学第二临床医学院
作者单位1.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
2.Asahi Life Fdn, Inst Adult Dis, Tokyo, Japan
3.Gangnam Severance Hosp, Seoul, South Korea
4.Eli Lilly & Co, Indianapolis, IN 46285 USA
5.Hormone Care & Res Ctr, Ghaziabad, India
6.Chi Mei Med Ctr, Tainan, Taiwan
7.PharmaNet i3, Ann Arbor, MI USA
8.PharmaNet i3, Blue Bell, PA USA
推荐引用方式
GB/T 7714
Ji, Linong,Onishi, Yukiko,Ahn, Chul Woo,et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus[J]. JOURNAL OF DIABETES INVESTIGATION,2013,4(1):53-61.
APA Ji, Linong.,Onishi, Yukiko.,Ahn, Chul Woo.,Agarwal, Pankaj.,Chou, Chien-Wen.,...&Boardman, Marilyn K..(2013).Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.JOURNAL OF DIABETES INVESTIGATION,4(1),53-61.
MLA Ji, Linong,et al."Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus".JOURNAL OF DIABETES INVESTIGATION 4.1(2013):53-61.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ji, Linong]的文章
[Onishi, Yukiko]的文章
[Ahn, Chul Woo]的文章
百度学术
百度学术中相似的文章
[Ji, Linong]的文章
[Onishi, Yukiko]的文章
[Ahn, Chul Woo]的文章
必应学术
必应学术中相似的文章
[Ji, Linong]的文章
[Onishi, Yukiko]的文章
[Ahn, Chul Woo]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。